Opinion

Video

ADCs Targeting HER2+ Lung Cancer

Author(s):

Vijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH

Dr Garon shares insights on the role of ADCs for the treatment of HER2+ lung cancer.

Video content above is prompted by the following:

  • Please review the data investigating T-DM1 for HER2+ NSCLC
    • Phase 2 trial (NCT02289833)
  • When and why should T-DXd be considered?
Related Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content